Keymed Makes Hong Kong Debut, Raises $378 million_老虎社区_美港股上老虎

Keymed Makes Hong Kong Debut, Raises $378 million

Investing.com2021-07-08

Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process. Keymed’s Hong Kong shares were at HK$70 by...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

105

acyilin
·2021-07-08
nice!
回复
点赞
举报
3f8c6d28
·2021-07-08
like can comment pls
回复
点赞
举报
Yumiko88
·2021-07-08
Like and comment
回复
3
举报
收起
- 3f8c6d28:
  like
  2021-07-08
  回复
  举报
Suet79
·2021-07-08
G
回复
1
举报
UpUpUpUpUp
·2021-07-08
Wow!!
回复
2
举报
alaric
·2021-07-08
Ususus
回复
1
举报
收起
- 7a3b0355:
  Like and comment
  2021-07-08
  回复
  举报
lizzy04
·2021-07-08
Haha
回复
3
举报
MrNewman
·2021-07-08
Nice!
回复
2
举报
收起
- lizzy04:
  yep
  2021-07-08
  回复
  举报
cgjy
·2021-07-08
[Miser]
回复
点赞
举报
Jarvis92
·2021-07-08
Like n comment pls
回复
8
举报
收起
- 猫山王77:
  Done. Like n comment back pls. 👍
  2021-07-08
  回复
  举报
- EriViL:
  Like pla
  2021-07-08
  回复
  举报
- 253f2e60:
  okay
  2021-07-08
  回复
  举报
查看更多 1 条评论
JustinMay
·2021-07-08
Cool!
回复
5
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-08 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169240809","market":"hk","top_or_hot":-1,"title":"Keymed Makes Hong Kong Debut, Raises $378 million","media":"Investing.com","content":"<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","article_id":"1169240809","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","pubTimestamp":1625748735,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"Keymed首次香港上市，融资3.78亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":143980829,"gmtCreate":1625755512261,"gmtModify":1633937632497,"author":{"id":"3579911378800254","authorId":"3579911378800254","name":"acyilin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3579911378800254","idStr":"3579911378800254"},"htmlText":"nice!","listText":"nice!","text":"nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143980829","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":143913360,"gmtCreate":1625755139350,"gmtModify":1633937637939,"author":{"id":"3581890280369523","authorId":"3581890280369523","name":"3f8c6d28","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581890280369523","idStr":"3581890280369523"},"htmlText":"like can comment pls","listText":"like can comment pls","text":"like can comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143913360","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":143042294,"gmtCreate":1625753695718,"gmtModify":1633937667918,"author":{"id":"4087355322223700","authorId":"4087355322223700","name":"Yumiko88","avatar":"https://static.tigerbbs.com/8de4f8ae37c793c2349956a9b50920f9","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4087355322223700","idStr":"4087355322223700"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/143042294","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5162865,"gmtCreate":1625755150325,"gmtModify":1635234033756,"authorId":3581890280369523,"author":{"id":3581890280369523,"idStr":"3581890280369523","authorId":3581890280369523,"name":"3f8c6d28","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":143042294,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"EN"},{"id":143022271,"gmtCreate":1625753182593,"gmtModify":1633937681772,"author":{"id":"3583389578129719","authorId":"3583389578129719","name":"Suet79","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3583389578129719","idStr":"3583389578129719"},"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143022271","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":143038158,"gmtCreate":1625752051174,"gmtModify":1633937710271,"author":{"id":"3575517733011286","authorId":"3575517733011286","name":"UpUpUpUpUp","avatar":"https://static.tigerbbs.com/f92e5e26e6e720eda3643248da3c21eb","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3575517733011286","idStr":"3575517733011286"},"htmlText":"Wow!!","listText":"Wow!!","text":"Wow!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143038158","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149740884,"gmtCreate":1625750629248,"gmtModify":1633937738164,"author":{"id":"3575165357870175","authorId":"3575165357870175","name":"alaric","avatar":"https://static.tigerbbs.com/b25fc239065aa81f222fd3662c8d2d99","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3575165357870175","idStr":"3575165357870175"},"htmlText":"Ususus","listText":"Ususus","text":"Ususus","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/149740884","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5161652,"gmtCreate":1625750711196,"gmtModify":1635234116025,"authorId":3583411958858523,"author":{"id":3583411958858523,"idStr":"3583411958858523","authorId":3583411958858523,"name":"7a3b0355","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149740884,"type":1,"supId":0,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":149753823,"gmtCreate":1625750279762,"gmtModify":1631890668657,"author":{"id":"3582761710994135","authorId":"3582761710994135","name":"lizzy04","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":13,"crmLevelSwitch":0,"authorIdStr":"3582761710994135","idStr":"3582761710994135"},"htmlText":"Haha","listText":"Haha","text":"Haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149753823","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149725780,"gmtCreate":1625750038140,"gmtModify":1633937744376,"author":{"id":"3575971055509237","authorId":"3575971055509237","name":"MrNewman","avatar":"https://static.tigerbbs.com/530fe22e84a93f106f3c10b865f30180","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3575971055509237","idStr":"3575971055509237"},"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/149725780","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5161588,"gmtCreate":1625750271177,"gmtModify":1635234121266,"authorId":3582761710994135,"author":{"id":3582761710994135,"idStr":"3582761710994135","authorId":3582761710994135,"name":"lizzy04","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":13,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149725780,"type":1,"supId":0,"prevId":0,"content":"yep","text":"yep","html":"yep"}],"langContent":"EN"},{"id":149723721,"gmtCreate":1625749782163,"gmtModify":1633937748270,"author":{"id":"3581498631806671","authorId":"3581498631806671","name":"cgjy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581498631806671","idStr":"3581498631806671"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149723721","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149788377,"gmtCreate":1625748848599,"gmtModify":1633937762142,"author":{"id":"4087992674383480","authorId":"4087992674383480","name":"Jarvis92","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4087992674383480","idStr":"4087992674383480"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/149788377","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5161386,"gmtCreate":1625748956872,"gmtModify":1635234137992,"authorId":3567656189229002,"author":{"id":3567656189229002,"idStr":"3567656189229002","authorId":3567656189229002,"name":"猫山王77","avatar":"https://static.tigerbbs.com/b0f449741d66eb9e2e9d062335702513","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":0,"prevId":0,"content":"Done. Like n comment back pls. 👍","text":"Done. Like n comment back pls. 👍","html":"Done. Like n comment back pls. 👍"},{"id":5161395,"gmtCreate":1625749043111,"gmtModify":1635234137360,"authorId":3577087216911488,"author":{"id":3577087216911488,"idStr":"3577087216911488","authorId":3577087216911488,"name":"EriViL","avatar":"https://static.tigerbbs.com/f37d027290c1cdf3fa6cdba6443077c6","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":0,"prevId":0,"content":"Like pla","text":"Like pla","html":"Like pla"},{"id":5161398,"gmtCreate":1625749055343,"gmtModify":1635234137234,"authorId":3563442467729531,"author":{"id":3563442467729531,"idStr":"3563442467729531","authorId":3563442467729531,"name":"253f2e60","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":5161386,"prevId":0,"content":"<u>okay</u>","text":"<u>okay</u>","html":"<u>okay</u>"},{"id":5161609,"gmtCreate":1625750429040,"gmtModify":1635234119644,"authorId":3569375896365334,"author":{"id":3569375896365334,"idStr":"3569375896365334","authorId":3569375896365334,"name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":5161395,"prevId":0,"content":"Like and comment <u>pls</u>","text":"Like and comment <u>pls</u>","html":"Like and comment <u>pls</u>"}],"langContent":"EN"},{"id":149781184,"gmtCreate":1625748819648,"gmtModify":1631889064995,"author":{"id":"3581997079623763","authorId":"3581997079623763","name":"JustinMay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581997079623763","idStr":"3581997079623763"},"htmlText":"Cool!","listText":"Cool!","text":"Cool!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/149781184","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://www.laohu8.com/m/news/1169240809?lang=zh_CN&edition=full","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million<blockquote>Keymed在香港首次亮相，融资3.78亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2021-07-08 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p><p><blockquote>Investing.com—Keymed Biosciences Inc.（HK：2162）在香港联交所上市，并在此过程中筹集了29.4亿港元（3.7848亿美元）。</blockquote></p><p> Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p><p><blockquote>截至美国东部时间凌晨1:32（格林威治标准时间凌晨5:32），Keymed的香港股价为70港元，开盘上涨46.3%，至78美元。该公司以每股53.3港元发售5826万股，为50.5港元至53.3港元区间的上限。</blockquote></p><p> Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p><p><blockquote>在2021年6月底启动股票销售的20多家公司中，Keymed是认购最多的候选公司之一。散户投资者为该公司股票下了价值532亿港元的订单，超额认购171倍。共有15名基石投资者也认购了价值14.8亿港元的股份，约占发行总额的50%。</blockquote></p><p> The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p><p><blockquote>投资者名单包括景顺、瑞银资产管理、淡马锡、高瓴资本、Lake Bleu Capital和石药制药。据报道，该公司还能够比预期提前一天关闭机构账簿。</blockquote></p><p> Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p><p><blockquote>Keymed成立于2016年，总部位于中国成都，开发治疗癌症和自身免疫性疾病的疗法。它有九种候选药物已被批准为研究新药，并正在对其中五种进行临床试验。</blockquote></p><p> However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p><p><blockquote>然而，由于预计在2023年之前没有一种候选药物能够商业化，Keymed尚未从产品销售中产生利润。由于研发投资和管理费用增加，该公司2020年净亏损扩大3.89倍至8.188亿元人民币（1.2649亿美元）。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Investing.com</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1,"symbols_score_info":{"02162":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":105,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}